A Method for Automatically Extracting Domain Semantic Networks from Wikipedia

C. Xavier,Vera Lúcia Strube de Lima

DOI: https://doi.org/10.1007/978-3-642-28885-2_10

2012-04-17

Abstract:

What problem does this paper attempt to address?

A population‐based case‐control study of human papillomavirus‐type‐16 seropositivity and incident high‐grade dysplasia of the uterine cervix

A. O. Olsen,J. Dillner,K. Gjøen,T. Sauer,I. Ørstavik,P. Magnus

DOI: https://doi.org/10.1002/(SICI)1097-0215(19961115)68:4<415::AID-IJC2>3.0.CO;2-3

1996-11-15

International Journal of Cancer

Abstract:In order to study the association between seropositivity against human papillomavirus‐type‐16 capsids and CIN II‐III in the general population in ages at which high‐grade cervical dysplasia arises, 90 cases and 216 controls participating in a population‐based case‐control study of incident CIN II‐III, were analyzed for the presence of HPV antibodies, HPV DNA and for the influence of behavioral factors. A significantly higher proportion of cases than controls were seropositive. Of HPV‐16‐DNA‐positive cases and controls, 42 and 14% respectively were seropositive. A similar proportion of seropositivity was found among the 172 cytologically normal, HPV‐DNA‐negative controls. However, seropositivity was closely linked to the sexual history of the women. Logistic‐regression analyses, adjusting for sexual behavior, smoking history and educational level, revealed that CIN II‐III was associated with HPV‐16 seropositivity and with HPV DNA. Controlling for the presence of HPV DNA indicated that antibodies were not independently associated with CIN. The low correlation between the presence of HPV antibodies and DNA, the finding that the association between seropositivity and CIN depended on the presence of HPV DNA, and the association of seropositivity with sexual history, may be explained by serology detecting both past and present persistent infections and presence of HPV DNA, reflecting mostly transient infections in controls and persistent infections in cases. © 1996 Wiley‐Liss, Inc.
Das Lebensmittel-Monitoring – ein wichtiges Instrument zur Erfassung und Beurteilung von unerwünschten Stoffen in und auf Lebensmitteln

J. Müller,R. Binner,G. Henseler

DOI: https://doi.org/10.1007/s00003-006-0007-4

2006-02-01

Abstract:
Probiotics for Preventing Necrotizing Enterocolitis: A Meta-Analysis with Trial Sequential Analysis

Yang Zhang,Qiong Xu,Feng Zhang,Chunlei Sun

DOI: https://doi.org/10.1155/2023/8626191

2023-05-08

Journal of Clinical Pharmacy and Therapeutics

Abstract:What is Known and Objective. The role of probiotics, especially the different genera of probiotics, in managing necrotizing enterocolitis (NEC) is controversial. Thus, we performed a meta-analysis with trial sequential analysis (TSA) to determine the efficacy and safety of probiotics for preventing NEC. Methods. Medline, Embase, CENTRAL, WorldCat, TROVE, DART-Europe, and CBM were searched from inception to May 2022. Two investigators independently screened the literature, extracted data, and assessed the quality of the included studies. Meta-analysis was performed using RevMan 5.4, and TSA was conducted using TSA 0.9 beta. Results and Discussion. Fifty-five studies involving 12897 newborns were eligible. The use of probiotics for preventing NEC reduced the incidence of NEC (RR 0.48, 95% CI 0.41 to 0.57, and P < 0.05) and sepsis (RR 0.77, 95% CI 0.64 to 0.94, and P < 0.05), the risk of mortality (RR 0.69, 95% CI 0.58 to 0.84, and P < 0.05), and shortened the average days of hospitalization (MD −3.12, 95% CI −4.98 to −1.26, and P < 0.05). However, subgroup analysis revealed that different genera of probiotics gave rise to different outcomes. In addition, TSA indicated that the cumulative z-curve crossed the traditional and trial sequential monitoring boundaries for benefit, providing firm evidence that multiple strains and Lactobacillus species of probiotics decreased the incidence of NEC. However, the current evidence was inconclusive for Bifidobacterium and Saccharomyces species. What is New and Conclusions. Probiotics are effective in preventing NEC and sepsis and could provide added benefits, including decreasing mortality and the number of days of hospitalization. However, considering the heterogeneity of probiotics regimens and the risk of selective reporting of RCTs, more high-quality clinical trials targeting different genera of probiotics with suitable doses and timing to prophylactic use of probiotics are needed to avoid overestimating the role of probiotics in preterm infants.

pharmacology & pharmacy
Bifidobacterium and Lactobacillus for preventing necrotizing enterocolitis in very-low-birth-weight preterm infants: a systematic review and meta-analysis

Xue Jiao,Meng-Di Fu,Ya-Yun Wang,Jiang Xue,Yuan Zhang

DOI: https://doi.org/10.1007/s12519-019-00297-5

2019-01-01

World Journal of Pediatrics

Abstract:Background The therapeutic effect of Bifidobacterium and Lactobacillus on necrotizing enterocolitis (NEC) in very-low-birth-weight preterm infants was controversial, and we aimed to explore the exact impact of the two probiotics. Methods The PubMed, EMBASE, Web of Science and Cochrane Library were systematically searched for studies published from January 1, 2010 to February 28, 2019. Results were combined with fixed-effect model or random-effect model with specific conditions. Sensitivity analysis was conducted by the trim-and-fill method, and the Begger’s and Egger's test were used to measure publication bias. Results The meta-analysis included 16 original articles with 4632 very-low-birth-weight preterm infants. With respect to the intervention of Bifidobacterium , we estimated non-significant decrease in the morbidity of NEC with a risk ratio (RR) of 0.75 [95% confidence internal (CI) 0.56–1.01, P = 0.06]. Regarding the effect of Lactobacillus , there was no evidence of significant lower risk in the incidence of NEC (RR = 0.67, 95% CI 0.39–1.17, P = 0.16). The use of mixture of probiotics ( Bifidobacterium and Lactobacillus ) reduced the risk of NEC in the probiotics group (RR = 0.45, 95% CI 0.25–0.80, P = 0.007). Conclusion The mixture of Bifidobacterium and Lactobacillus could prevent the morbidity of NEC in very-low-birth-weight preterm infants. But Bifidobacterium or Lactobacillus alone did not show this effect.
Reliable and fast eye finding in close-up images

T. Camus,Richard P. Wildes

DOI: https://doi.org/10.1109/ICPR.2002.1044732

2002-08-11

Abstract:This paper describes a method for quickly and robustly localizing the iris and pupil boundaries of a human eye in close-up images. Such an algorithm can be critical for iris identification, or for applications that must determine the subject's gaze direction, e.g., human-computer interaction or driver attentiveness determination. A multi-resolution coarse-to-fine search approach is used, seeking to maximize gradient strengths and uniformities measured across rays radiating from a candidate iris or pupil's central point. An empirical evaluation of 670 eye images, both with and without glasses, resulted in a 98% localization accuracy. The algorithm has also shown robustness to weak illumination and most specular reflections (e.g., at eyewear and cornea), simplifying system component requirements. Rapid execution is achieved on a 750 MHz desktop processor.
Effect of probiotic supplementation on the gut microbiota in very preterm infants: a systematic review

Kayleigh Vievermanns,Thomas H Dierikx,Nathalie J Oldenburger,Faridi S Jamaludin,Hendrik J Niemarkt,Tim G J de Meij

DOI: https://doi.org/10.1136/archdischild-2023-326691

2024-06-26

Archives of Disease in Childhood - Fetal and Neonatal Edition

Abstract:Objective There is increasing evidence that probiotic supplementation in very preterm infants decreases the risk of necrotising enterocolitis (NEC), sepsis and mortality. The underlying mechanisms, including effects on the gut microbiota, are largely unknown. We aimed to systematically review the available literature on the effects of probiotic supplementation in very preterm infants on gut microbiota development. Design A systematic review in Medline, Embase, Cochrane Library, CINAHL and Web of Science. Setting Neonatal intensive care unit. Patients Premature infants. Intervention Probiotic supplementation. Main outcome measures Gut microbiota. Results A total of 1046 articles were screened, of which 29 were included. There was a large heterogeneity in study design, dose and type of probiotic strains, timepoints of sample collection and analysing techniques. Bifidobacteria and lactobacilli were the most used probiotic strains. The effects of probiotics on alpha diversity were conflicting; however, beta diversity was significantly different between probiotic-supplemented infants and controls in the vast majority of studies. In most studies, probiotic supplementation led to increased relative abundance of the supplemented strains and decreased abundance of genera such as Clostridium , Streptococcus , Klebsiella and Escherichia . Conclusions Probiotic supplementation to preterm infants seems to increase the relative abundance of the supplemented strains with a concurrent decrease of potentially pathogenic species. These probiotic-induced microbial alterations may contribute to the decreased risk of health complications such as NEC. Future trials, including omics technologies to analyse both microbiota composition and function linked to health outcomes, are warranted to identify the optimal mixture and dosing of probiotic strains. PROSPERO registration number CRD42023385204.

pediatrics
Probiotics vs. Placebo: Preventing Necrotizing Enterocolitis in a Premature Infant

Sami Ullah,Inayatullah Khan,Ayesha Lnu,Jabran Ullah Khan,Annam Syed,Fatima Shafiq,Muhammad Khan,Fahad R Khan

DOI: https://doi.org/10.7759/cureus.68848

2024-09-07

Cureus

Abstract:Background: Necrotizing enterocolitis (NEC) is a severe gastrointestinal condition primarily affecting preterm newborns, leading to significant morbidity and mortality. Objective: This prospective cohort study aimed to evaluate the effectiveness of probiotics in preventing NEC in premature infants. Secondary objectives included assessing the impact on mortality, late-onset sepsis, duration of hospital stay, and weight gain. Methods: The study was conducted at Lady Reading Hospital Medical Teaching Institute, Peshawar, from April 1, 2023, to March 31, 2024, involving 102 preterm infants. Participants were randomly assigned to receive daily oral probiotics (Lactobacillus and Bifidobacterium species) or a placebo. Results: The incidence of NEC was significantly lower in the probiotic group (7.8%) compared to the placebo group (21.6%; p = 0.04). The probiotic group also showed significant reductions in late-onset sepsis (13.7% vs. 29.4%; p = 0.03), shorter hospital stays (42.5 vs. 48.1 days; p = 0.02), and greater weight gain (15.3 vs. 13.4 grams/day; p = 0.01). Conclusion: These findings support the integration of probiotics into neonatal care, particularly in resource-limited settings.
Benefits of probiotics in preterm neonates in low-income and medium-income countries: a systematic review of randomised controlled trials

Girish Deshpande,Gayatri Jape,Shripada Rao,Sanjay Patole

DOI: https://doi.org/10.1136/bmjopen-2017-017638

IF: 3.006

2017-12-01

BMJ Open

Abstract:Objective Although there is an overall reduction in underfive mortality rate, the progress in reducing neonatal mortality rate has been very slow. Over the last 20 years, preterm births have steadily increased in low-income and medium-income countries (LMICs) particularly in sub-Saharan Africa and South Asia. Preterm birth is associated with increased mortality and morbidity, particularly in LMICs. Based on systematic reviews of randomised controlled trials (RCTs), many neonatal units in high-income countries have adopted probiotics as standard of care for preterm neonates. We aimed to systematically review the safety and efficacy of probiotics in reducing mortality and morbidity in preterm neonates in LMICs. Design Systematic review and meta-analysis of RCTs. Data sources Medline, Embase, Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature and E-abstracts from Pediatric Academic Society meetings and other paediatric and neonatal conference proceedings were searched in January 2017. Eligibility criteria RCTs comparing probiotics versus placebo/no probiotic in preterm neonates (gestation<37 weeks) conducted in LMICs. Results Total 23 (n=4783) RCTs from 4 continents and 10 LMICs were eligible for inclusion in the meta-analysis using fixed effect model. The risk of necrotising enterocolitis (NEC greater than or equal to stage II) (risk ratio (RR) 0.46 (95% CI 0.34 to 0.61), P<0.00001, numbers needed to treat (NNT) 25 (95% CI 20 to 50)), late-onset sepsis (LOS) (RR 0.80 (95% CI 0.71 to 0.91), P=0.0009, NNT 25 (95% CI 17 to 100)) and all-cause mortality (RR 0.73 (95% CI 0.59 to 0.90), P=0.003, NNT 50 (95% CI 25 to 100)) were significantly lower in probiotic supplemented neonates. The results were significant on random effects model analysis and after excluding studies with high risk of bias. No significant adverse effects were reported. Conclusion Probiotics have significant potential to reduce mortality and morbidity (eg, NEC, LOS) in preterm neonates in LMICs.

medicine, general & internal
Efficacy of Probiotics Versus Placebo in the Prevention of Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants: A Double-Blind Randomized Controlled Trial

Tanjina Chowdhury,Muhammad Manajjir Ali,Muhammad Monir Hossain,Jugindra Singh,Abu Noyeem Muhammad Yousuf,Fatema Yasmin,Fazle Rabbi Chowdhury

Abstract:Objective: To evaluate the efficacy of orally administered probiotics in preventing necrotizing enterocolitis (NEC) in preterm very low birth weight (VLBW) infants. Study design: Arandomized double blind controlled trial. Place and duration of study: The Paediatrics Department of Sylhet M.A.G. Osmani Medical College Hospital, Sylhet Bangladesh, from July 2012 to June 2015. Methodology: Preterm (28 - 33 weeks gestation) VLBW (birth weight 1000 - 1499 g) neonates were enrolled. The study group was fed with probiotics once daily with breast milk from first feeding, and the control group with only breast milk without the addition of probiotics. Both the groups received other standard care. The primary outcome was the development of NEC (stage II and III), categorized by modified Bell's classification. Results: In 108 neonates, development of NEC was significantly lower in the study group than that of control group [1 (1.9%) vs. 6 (11.5%); p=0.044]. Age of achievement of full oral feeding was significantly earlier in the study group than that in the control group (14.88 ±3.15 and 18.80 ±4.32 days; p < 0.001). Duration of hospital stay was significantly short in the study group compared to the control group (15.82 ±2.94 days vs. 19.57 ±4.26 days; p < 0.001). Conclusion: Probiotic supplementation reduces the frequency of necrotising enterocolitis in preterm neonates with very low birth weight. It is also associated with faster achievement of full oral feeding and short duration of hospital stay.
The Effect of Oral Probiotics on the Prevention of Necrotizing Enterocolitis in Preterm Infants:A Meta-Analysis of Its Efficacy and Safety

程国强,王来栓,周文浩

DOI: https://doi.org/10.3969/j.issn.1673-5501.2009.06.002

2009-01-01

Abstract:Objective To compare the efficacy and safety of prophylactic enteral probiotics administration versus placebo or no treatment in the prevention of severe NEC and sepsis in preterm infants.Methods Standard search strategy for the Cochrane Neonatal Review Group was performed by two review authors.Searches were made in PubMed,EMBASE,Ovid,Springer and CNKI databases with the terms Preterm or newborn or infants or very low birth weight or extremely low birth weight and probiotics or lactobacillus or bifidobactrium or saccharomyces and necrosis enterocolitis.Only randomized or quasi-randomized controlled trials which involved enteral administration of any live microbial supplement(probiotics) and measured at least one prespecified clinical outcome such as morbidity of severe NEC,sepsis or mortality were considered.Standard methods of the Cochrane Collaboration and its Neonatal Group were used to assess the methodological quality of the trials.RevMan 4.22 software was used to make meta analysis.Results 107 literatures were reviewed.The studies including full-term infants RCTs(n=52),reviews(n=17),commentators(n=4),documents not meeting the major results of the meta analysis(n=15),case-control studies(n=3),self-control studies(n=2),not randomized studies(n=2),data undetailed and to contact the author unsuccessfully studies(n=10) were excluded.Ten eligible trials randomizing 2 117 infants(1 056 of treatment group and 1 061 of control group) were included.The results of quality assessment were that 8 studies were A,1 was B and 1 was C.Included trials were highly variable with regard to enrollment criteria such as birth weight and gestational age,baseline risk of NEC in the control group,timing,dose,formulation of the probiotics,and feeding regimens.Data regarding extremely low birth weight(ELBW) infants were few.In a meta analysis of trial data,enteral probiotics supplementation significantly reduced the incidence of severe NEC(stage Ⅱ or above)(OR=0.34,95%CI:0.22-0.55) and mortality(OR=0.36,95% CI:0.22-0.58).There was no evidence on significant incidence reduction in nosocomial sepsis(OR=0.94,95%CI:0.62-1.42) or in NEC-related deaths(OR=0.48,95%CI:0.16-1.47).The hospilized days were longer in treatment group than that in control group(P0.01).The included trials were reported no systemic infection with the probiotics supplemental organism.Conclusions Enteral supplementation of probiotics reduced the risk of severe NEC and mortality in preterm infants.This analysis supports a change in practice in premature infants 1 000 g at birth.The safety and efficacy of administration of probiotic supplements couldn't be made in ELBW.A large randomized controlled trial is required to investigate the potential benefits and safety profile of probiotics supplementation in ELBW infants.
Probiotics for prevention of necrotizing enterocolitis and sepsis in preterm infants

Nicholas D Embleton,Stefan Zalewski,Janet E Berrington

DOI: https://doi.org/10.1097/QCO.0000000000000269

Abstract:Purpose of review: Few areas in neonatal medicine have generated as much discussion and controversy as the use of prophylactic probiotics for the prevention of necrotizing enterocolitis. We summarize recent studies from the last 1-2 years. Recent findings: Systematic reviews show that probiotics reduce the risk of necrotizing enterocolitis but there are methodological limitations to all the published trials, and the largest trial to date is at odds with the conclusions of the meta-analyses. Trials have used a range of commercially available products with differing species, and administered these at different times to heterogeneous populations of preterm babies. Although there is strong evidence to show that 'probiotics' are likely to represent a major advance for neonatal care, it is increasingly clear that not all species have beneficial effects in preterm infants. This makes interpretation of meta-analyses complex, and the determination of a single 'risk reduction' potentially flawed. Summary: Despite current uncertainties, it is difficult for clinicians to ignore the current data, and increasing numbers now use commercially available products. It remains a matter of concern that many products lack the robust quality control most clinicians and parents would consider important for use in vulnerable populations. Head-to-head trials are needed.
Incidence of necrotising enterocolitis before and after introducing routine prophylactic Lactobacillus and Bifidobacterium probiotics

Claire Robertson,George M Savva,Raducu Clapuci,Jacqueline Jones,Hassan Maimouni,Eleanor Brown,Ashish Minocha,Lindsay J Hall,Paul Clarke

DOI: https://doi.org/10.1136/archdischild-2019-317346

2019-10-30

Abstract:Objective To compare rates of necrotising enterocolitis (NEC), late-onset sepsis, and mortality in 5-year epochs before and after implementation of routine daily multistrain probiotics administration in high-risk neonates. Design Single-centre retrospective observational study over the 10-year period from 1 January 2008 to 31 December 2017. Setting Level 3 neonatal intensive care unit (NICU) of the Norfolk and Norwich University Hospital, UK. Patients Preterm neonates at high risk of NEC: admitted to NICU within 3 days of birth at <32 weeks’ gestation or at 32–36 weeks’ gestation and of birth weight <1500 g. Intervention Prior to 1 January 2013 probiotics were not used. Thereafter, dual-species Lactobacillus acidophilus and Bifidobacterium bifidum combination probiotics were routinely administered daily to high-risk neonates; from April 2016 triple-species probiotics ( L. acidophilus, B. bifidum, and B. longum subspecies infantis ) were used. Main outcome measures Incidence of NEC (modified Bell’s stage 2a or greater), late-onset sepsis, and mortality. Results Rates of NEC fell from 7.5% (35/469 neonates) in the pre-implementation epoch to 3.1% (16/513 neonates) in the routine probiotics epoch (adjusted sub-hazard ratio=0.44, 95% CI 0.23 to 0.85, p=0.014). The more than halving of NEC rates after probiotics introduction was independent of any measured covariates, including breast milk feeding rates. Cases of late-onset sepsis fell from 106/469 (22.6%) to 59/513 (11.5%) (p<0.0001), and there was no episode of sepsis due to Lactobacillus or Bifidobacterium . All-cause mortality also fell in the routine probiotics epoch, from 67/469 (14.3%) to 47/513 (9.2%), although this was not statistically significant after multivariable adjustment (adjusted sub-hazard ratio=0.74, 95% CI 0.49 to 1.12, p=0.155). Conclusions Administration of multispecies Lactobacillus and Bifidobacterium probiotics has been associated with a significantly decreased risk of NEC and late-onset sepsis in our neonatal unit, and no safety issues. Our data are consistent with routine use of Lactobacillus and Bifidobacterium combination probiotics having a beneficial effect on NEC prevention in very preterm neonates.
The "pro" and "con" of probiotics, regulation and preterm infant health

Shetal Shah

DOI: https://doi.org/10.1038/s41390-024-03766-4

IF: 3.953

2024-12-06

Pediatric Research

Abstract:Necrotizing Enterocolitis (NEC) is among the most devastating complications of preterm birth, with ~25% mortality among very low birthweight (VLBW) infants. 1,2,3 Among survivors, the condition can impart long-term negative health effects, occurring both before and after the index neonatal hospitalization. 1,2,3 Babies born at extremely low birthweight (ELBW) are more vulnerable, and mortality surpasses 40% for infants in need of surgery. 4,5,6 Survivors of NEC require significant resources to meet ongoing healthcare needs, as afflicted infants are at risk for short gut syndrome, liver disease and intestinal failure. 5,6,7,8,9 Beyond the neonatal period, infants with NEC exhibit double the odds of neurodevelopmental impairment, independent of additional risk conferred by intraventricular hemorrhage and periventricular leukomalacia. 10,11 This care is costly, and NEC remains a major source of healthcare utilization. Direct costs of NEC alone are estimated from 600,000 per case of surgical NEC. 12,13,14 Surgical NEC is the costliest diagnosis in children's hospitals, with even higher costs associated with lower gestational age at time of diagnosis. 15 Total annual spending on NEC approaches $1 Billion. 4 Despite its devastating impact, treatment for NEC has not dramatically changed in decades. Bowel rest, antibiotics and supportive care remain mainstays of treatment. Though the mechanism of NEC is not fully known, greater progress has been made in prevention among VLBW infants. Receipt of antenatal steroids, along with postnatal strategies such as early enteral feeding, reductions in early and prolonged antibiotic exposure, use of standardized feeding protocols, promotion of skin-to-skin contact and human milk diets are all associated with reductions in NEC. 16,17,18,19,20

pediatrics
Effects of Probiotics in Preterm Infants: A Network Meta-analysis

Cheng Chi,Cheng Li,Nicholas Buys,Wenjun Wang,Chenghong Yin,Jing Sun

DOI: https://doi.org/10.1542/peds.2020-0706

2021-01-01

PEDIATRICS

Abstract:CONTEXT: Probiotics have proven to be effective in promoting premature infants’ health, but the optimal usage is unknown. OBJECTIVE: To compare probiotic supplements for premature infants. DATA SOURCES: We searched PubMed, Embase, Cochrane, and ProQuest from inception of these databases to June 1, 2020. STUDY SELECTION: Randomized trials of probiotic supplement intervention for preterm infants were screened by 2 reviewers independently. The primary outcomes were mortality and the morbidity of necrotizing enterocolitis (NEC). Secondary outcomes were morbidity of sepsis, time to achieve full enteral feeding, and length of hospital stay. DATA EXTRACTION: The data of primary and secondary outcomes were extracted by 2 reviewers and pooled with a random-effects model. RESULTS: The meta-analysis included 45 trials with 12 320 participants. Bifidobacterium plus Lactobacillus was associated with lower rates of mortality (risk ratio 0.56; 95% credible interval 0.34–0.84) and NEC morbidity (0.47; 0.27–0.79) in comparison to the placebo; Lactobacillus plus prebiotic was associated with lower rates of NEC morbidity (0.06; 0.01–0.41) in comparison to the placebo; Bifidobacterium plus prebiotic had the highest probability of having the lowest rate of mortality (surface under the cumulative ranking curve 83.94%); and Lactobacillus plus prebiotic had the highest probability of having the lowest rate of NEC (surface under the cumulative ranking curve 95.62%). LIMITATIONS: In few studies did authors report the data of infants with a lower birth weight or gestational age. CONCLUSIONS: The efficacy of single probiotic supplements is limited, compared to combined use of probiotics. To achieve optimal effect on premature infant health, combined use of prebiotic and probiotic, especially Lactobacillus or Bifidobacterium, is recommended.

pediatrics
AlAr3(THF): highly efficient reagents for cross-couplings with aryl bromides and chlorides catalyzed by the economic palladium complex of PCy3.

Shih-Lun Ku,Xin-Ping Hui,Chien-an Chen,Yi-Ying Kuo,H. Gau

DOI: https://doi.org/10.1039/B707703C

IF: 4.9

2007-09-18

Chemical Communications

Abstract:Novel and highly efficient cross couplings of aryl bromides and chlorides with AlAr3(THF) (Ar = Ph, 2,4,6-Me3C6H2, 2-naphthyl or 4-Me3SiC6H4) catalyzed by the economic palladium catalyst of PCy3 are reported without the use of a base and under mild reaction conditions at room temperature or temperatures < or = 60 degrees C even for couplings of bulky aryl halides and the Al(2,4,6-Me3C6H2)3(THF) reagent.
Impact of Clinical Use of Probiotics on Preterm-Related Outcomes in Infants with Extremely Low Birth Weight

Wei-Hung Wu,Ming-Chou Chiang,Ren-Huei Fu,Mei-Yin Lai,I-Hsyuan Wu,Reyin Lien,Chien-Chung Lee

DOI: https://doi.org/10.3390/nu16172995

IF: 5.9

2024-09-05

Nutrients

Abstract:Background: Preterm birth significantly contributes to mortality and morbidities, with recent studies linking these issues to gut microbiota imbalances. Probiotic supplementation shows promise in mitigating adverse outcomes in preterm infants, but optimal timing and guidelines remain unclear. This study assesses the benefits of probiotic supplementation for preterm infants without consistent guidelines. Methods: This retrospective study examined extremely low-birth-weight (ELBW) infants in neonatal intensive care units from 2017 to 2021. Mortality and preterm-related outcomes were compared between infants receiving probiotics and those not. Subgroup analyses based on probiotic initiation timing were conducted: early (≤14 days), late (>14 days), and non-probiotic groups. Results: The study included 330 ELBW infants: 206 received probiotics (60 early, 146 late), while 124 did not. Probiotic supplementation was associated with lower overall mortality (adjusted OR 0.22, 95% CI 0.09-0.48) and decreased mortality from necrotizing enterocolitis (NEC) or late-onset sepsis (LOS) (adjusted OR 0.12, 95% CI 0.03-0.45). Early probiotics reduced overall mortality, NEC/LOS-related mortality, and NEC/LOS-unrelated mortality. Late probiotics decreased overall mortality and NEC/LOS-related mortality. Early probiotic use also expedited full enteral feeding achievement. Conclusions: Probiotic supplementation reduces mortality and improves feeding tolerance in preterm infants. Establishing guidelines for probiotic use in this population is crucial.
Probiotics for the postoperative management of term neonates after gastrointestinal surgery

Amit Trivedi,Edward Teo,Karen S Walker

DOI: https://doi.org/10.1002/14651858.cd012265.pub2

IF: 8.4

2024-01-23

Cochrane Database of Systematic Reviews

Abstract:BACKGROUND: The intestinal microflora has an essential role in providing a barrier against colonisation of pathogens, facilitating important metabolic functions, stimulating the development of the immune system, and maintaining intestinal motility. Probiotics are live microorganisms that can be administered to supplement the gut flora. Neonates who have undergone gastrointestinal surgery are particularly susceptible to infectious complications in the postoperative period. This may be partly due to a disruption of the integrity of the gut and its intestinal microflora. There may be a role for probiotics in reducing the incidence of sepsis and improving intestinal motility, thus reducing morbidity and mortality and improving enteral feeding in neonates in the postoperative period.OBJECTIVES: To evaluate the efficacy and safety of administering probiotics after gastrointestinal surgery for the postoperative management of neonates born from 35 weeks of gestation.SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, and trial registries in August 2023. We checked reference lists of included studies and relevant systematic reviews for additional studies.SELECTION CRITERIA: We included randomised controlled trials (RCTs) that investigated the postoperative administration of oral probiotics versus placebo or no treatment in neonates born from 35 weeks of gestation who had one or more gastrointestinal surgical procedures. We applied no restrictions regarding the type or dosage of probiotics or the duration of treatment.DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods, and we used GRADE to assess the certainty of evidence.MAIN RESULTS: We identified one RCT that recruited 61 neonates with a gestational age of 35 weeks or more. All infants were admitted to a neonatal intensive care unit and had surgery for gastrointestinal pathologies. There may be little or no difference in proven sepsis (positive bacterial culture, local or systemic) between infants who receive probiotics compared with those who receive placebo (odds ratio (OR) 0.64, 95% confidence interval (CI) 0.16 to 2.55; 61 infants; low-certainty evidence). Probiotics compared to placebo may have little or no effect on time to full enteral feeds (mean difference (MD) 0.63 days, 95% CI -4.02 to 5.28; 61 infants; low-certainty evidence). There were no reported deaths prior to discharge from hospital in either study arm. Two weeks after supplementation, the infants who received probiotics had a substantially higher relative abundance of non-pathogenic intestinal microflora (Bifidobacteriaceae) than those who received placebo (MD 38.22, 95% CI 28.40 to 48.04; 39 infants; low-certainty evidence).AUTHORS' CONCLUSIONS: This review provides low-certainty evidence from one small RCT that probiotics compared to placebo have little or no effect on the risk of proven sepsis (positive bacterial culture, local or systemic) or time to full-enteral feeds in neonates who have undergone gastrointestinal surgery. Probiotics may substantially increase the abundance of beneficial bacterial in the intestine of these neonates, but the clinical implications of this finding are unknown. There is a need for adequately powered RCTs to assess the role of probiotics in this population. We identified two ongoing studies. As neither reported the gestational age of prospective study participants, we are unsure if they will be eligible for inclusion in this review.

medicine, general & internal
Impact of probiotics on gut microbiome of extremely preterm or extremely low birthweight infants

Lauren C. Beck,Janet E. Berrington,Christopher J. Stewart

DOI: https://doi.org/10.1038/s41390-024-03520-w

IF: 3.953

2024-08-27

Pediatric Research

Abstract:Meta-analysis of probiotic administration to very preterm or very low birthweight (VP/VLBW) infants shows reduced risk of necrotising enterocolitis (NEC).

pediatrics
Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum) prevent NEC in VLBW infants fed breast milk but not formula

Andreas Repa,Margarita Thanhaeuser,David Endress,Michael Weber,Alexandra Kreissl,Christoph Binder,Angelika Berger,Nadja Haiden

DOI: https://doi.org/10.1038/pr.2014.192

IF: 3.953

2014-11-25

Pediatric Research

Abstract:Background:Specific probiotics prevent necrotizing enterocolitis (NEC). A mixture of lactobacilli and bifidobacteria (Infloran) was highly effective in Asian very-low-birth-weight (VLBW) infants. We analyzed the effect of Infloran on NEC, NEC severity, and the influence of enteral feedings (breast milk vs. formula) on NEC prevention in a cohort of European VLBW infants.Methods:Infloran was implemented for routine use at our department. VLBW infants receiving probiotics were prospectively followed (2010–2012) and compared with historic controls (2008–2009). Data on NEC, neonatal morbidity, feeding tolerance, and descriptive parameters on NEC cases were analyzed.Results:Infloran had no statistically significant impact on NEC (controls: 24/233 (10.3%); probiotics: 16/230 (7%); P = 0.2). However, NEC was significantly reduced in infants of the probiotics group who were fed any breast milk (20/179 (11.2%) vs. 10/183 (5.5%); P = 0.027), whereas it was ineffective in infants exclusively fed formula (4/54 (7.4%) vs. 6/44 (13.6%); P = 0.345). Occurrence of severe NEC (IIIb), time until full feeds, and gastric residuals were similar.Conclusion:Infloran was of lower efficacy in a European VLBW cohort and showed a reduction of NEC only in infants fed breast milk. Future studies should investigate the influence of feeding formula or breast milk on the effect of probiotics.

pediatrics
Evidence on the benefits of probiotics for preterm infants

Ana Maria Campos Martinez,Carmen Elizabeth Fernández Marín,Aida Ruiz López,Isabel Cubero Millán,José Uberos Fernández

DOI: https://doi.org/10.20960/nh.03743

2024-08-29

Abstract:This article reviews the evidence for the use of different strains of probiotics in the prevention of prevalent pathologies in premature neonates. A systematic review was conducted of the use of probiotics in neonates with less than 37 weeks of gestational age, based on a search for systematic reviews and observational and experimental studies performed during the period from January 2014 to February 2021. For this purpose, the PubMed, MEDLINE and Cochrane Library databases were consulted. The aim of this article was to review the existing data on the relationship between the administration of probiotics (with different strains and doses) and the risk of necrotising enterocolitis, mortality, late sepsis and other disease parameters in premature infants. The literature search obtained 240 articles, of which we selected 16, representing a total sample of over 200,000 premature infants. Analysis of the data obtained reveals statistical evidence that the combined administration of probiotics (especially of Lactobacillus and Bifidobacterium strains) reduces the incidence of grade II or higher necrotising enterocolitis, all-cause mortality, late sepsis, length of hospital stay and time until complete enteral nutrition is achieved. However, no benefits were apparent with respect to alleviating bronchopulmonary dysplasia, retinopathy of prematurity or intraventricular haemorrhage. Further research is needed to determine the most appropriate strains, doses and treatment duration for preterm infants to achieve the health benefits identified.

A Method for Automatically Extracting Domain Semantic Networks from Wikipedia

A population‐based case‐control study of human papillomavirus‐type‐16 seropositivity and incident high‐grade dysplasia of the uterine cervix

Das Lebensmittel-Monitoring – ein wichtiges Instrument zur Erfassung und Beurteilung von unerwünschten Stoffen in und auf Lebensmitteln

Probiotics for Preventing Necrotizing Enterocolitis: A Meta-Analysis with Trial Sequential Analysis

Bifidobacterium and Lactobacillus for preventing necrotizing enterocolitis in very-low-birth-weight preterm infants: a systematic review and meta-analysis

Reliable and fast eye finding in close-up images

Effect of probiotic supplementation on the gut microbiota in very preterm infants: a systematic review

Probiotics vs. Placebo: Preventing Necrotizing Enterocolitis in a Premature Infant

Benefits of probiotics in preterm neonates in low-income and medium-income countries: a systematic review of randomised controlled trials

Efficacy of Probiotics Versus Placebo in the Prevention of Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants: A Double-Blind Randomized Controlled Trial

The Effect of Oral Probiotics on the Prevention of Necrotizing Enterocolitis in Preterm Infants:A Meta-Analysis of Its Efficacy and Safety

Probiotics for prevention of necrotizing enterocolitis and sepsis in preterm infants

Incidence of necrotising enterocolitis before and after introducing routine prophylactic Lactobacillus and Bifidobacterium probiotics

The "pro" and "con" of probiotics, regulation and preterm infant health

Effects of Probiotics in Preterm Infants: A Network Meta-analysis

AlAr3(THF): highly efficient reagents for cross-couplings with aryl bromides and chlorides catalyzed by the economic palladium complex of PCy3.

Impact of Clinical Use of Probiotics on Preterm-Related Outcomes in Infants with Extremely Low Birth Weight

Probiotics for the postoperative management of term neonates after gastrointestinal surgery

Impact of probiotics on gut microbiome of extremely preterm or extremely low birthweight infants

Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum) prevent NEC in VLBW infants fed breast milk but not formula

Evidence on the benefits of probiotics for preterm infants